Vicapsys Acquires NitroMist and Establishes Federal Supply Channels
What happened
Vicapsys Life Sciences, Inc. completed a reverse merger with Stateline Distributors of Puerto Rico, Inc. on September 3, 2026, and acquired the FDA-approved NitroMist® (nitroglycerin) lingual aerosol product via a definitive asset purchase agreement. The combined company now operates as a pharmaceutical distributor and has established access to federal contracting channels, including Indian Health Service pharmaceutical supply.
From pr-inside.com
Why it matters
The acquisition and establishment of federal supply channels allow the combined company to participate in government healthcare procurement. This access is significant for the distribution and sales of the specialized pharmaceutical product.
From pr-inside.com
Who's involved
- FDAThe regulatory body whose approval is required for the product.
- Indian Health ServiceA federal supply channel the combined company can access for pharmaceutical distribution.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Indian Health ServiceSpeculative
The Indian Health Service might see changes in pharmaceutical supply contracts due to the combined company's new access.
Keep exploring
The entities involved
- FDA
-
Puerto Rico
unincorporated territory of the United States of America
Related events
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- Unregulated products are bypassing official government approval processes.
- NIH data informs market need for a device that requires FDA clearance to achieve Medicare coverage.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.